nifedipine has been researched along with Body Weight in 114 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this double-blind forced titration study design we compared the effects of mibefradil 50, 100, and 150 mg and nifedipine GITS 30, 60, and 90 mg monotherapies or combined with lisinopril 20 mg in 71 moderate to severe hypertensives (59 men and 12 women) with confirmed ambulatory hypertension." | 9.08 | The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. ( Archambault, F; Dalle Ave, S; Lacourcière, Y; Lefebvre, J; Lindberg, E; Poirier, L; Ward, C, 1997) |
| "Forty-nine patients, with ages ranging from eighteen to seventy years and with mild to moderate primary hypertension (sitting diastolic blood pressure of greater than or equal to 95 mmgH and less than or equal to 115 mmHg) were randomized into a twenty-one-week, double-blind, prospective study to determine the effects of monotherapy of nifedipine GITS (gastrointestinal therapeutic system) versus atenolol on serum lipids, lipid subfractions, apolipoproteins, (apo), and blood pressure (BP)." | 9.07 | Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. ( Burger, MC; Houston, MC; Olafsson, L, 1991) |
| "Thirty-nine patients with mild to moderate essential hypertension participated in a parallel, single-blind study comparing 6 weeks' treatment of nicardipine hydrochloride (90 mg/day) with nifedipine (40 mg/day)." | 9.06 | Comparison of the efficacy of nicardipine, a new calcium channel blocker, with nifedipine in the treatment of mild to moderate essential hypertension. ( Armstrong, C; Blackwood, R; Garnham, J, 1987) |
| "The effects of the addition of a calcium entry antagonist, nifedipine (20-mg tablet twice a day), to an angiotensin converting enzyme inhibitor, captopril (25 mg three times a day), and the addition of captopril to nifedipine were observed in two separate studies in patients with essential hypertension." | 9.06 | Captopril and nifedipine in combination for moderate to severe essential hypertension. ( MacGregor, GA; Markandu, ND; Shore, AC; Singer, DR, 1987) |
| "Nifedipine, in the gastrointestinal therapeutic system (GITS) formulation, a controlled-release formulation for once-a-day administration, was evaluated in the Modern Approach to the Treatment of Hypertension (MATH) trial." | 9.06 | Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. ( Bravo, EL; Friedman, CP; Krakoff, LR; Tuck, ML, 1990) |
| "The efficacy and safety of a new slow-release formulation of nifedipine ("Adalat Retard") were assessed in a double-blind cross-over trial in 19 subjects with essential hypertension (14 male, 5 female--ages: 34-72 years), 14 of whom continued previous antihypertensive medication." | 9.05 | Slow-release nifedipine as a single or additional agent in the treatment of essential hypertension--a placebo-controlled crossover study. ( Bune, AJ; Chalmers, JP; West, MJ; Wing, LM, 1985) |
| "A controlled multicentre trial was organised to compare the effects of 20 mg Nifedipine tablets (N) and 2,5 mg Indapamide tablets (I) during a 4 months' treatment period after a placebo period, in 59 patients with moderate essential hypertension (n = 59)." | 9.05 | [Comparative effects of nifedipine and indapamide in the treatment of arterial hypertension]. ( Aubert, P; Chaignon, M; Guédon, J; Lucsko, M; Rapoud, JP, 1985) |
| "The aim of this study was to compare the new vasodilator felodipine with nifedipine in 18 patients with poorly controlled hypertension." | 9.05 | Comparative trial of felodipine and nifedipine in refractory hypertension. ( Aberg, H; Lindsjö, M; Mörlin, B, 1985) |
| "Fifty-one patients with essential hypertension, 22 males and 29 females with a mean age of 51 (range, 28 to 65 years), were studied for more than 12 months in a controlled clinical trial with nitrendipine, a new calcium antagonist agent." | 9.05 | Clinical experience with long-term nitrendipine treatment in essential hypertension. ( Lasaridis, A; Settas, L; Tourkantonis, A, 1984) |
| "The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study." | 9.05 | Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Petitto, M; Santomauro, M; Villari, B, 1985) |
| "In a double-blind, cross-over study for 6 weeks that included 28 patients with essential hypertension, WHO stage I-II, the hypotensive action of verapamil (160 mg thrice daily) was compared with nifedipine (20 mg slow release twice daily)." | 9.05 | Verapamil compared with nifedipine in the treatment of essential hypertension. ( Hals, O; Midtbø, K; van der Meer, J, 1982) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 7.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 7.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 7.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 7.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| "To evaluate the use of short-acting nifedipine for treatment of severe hypertension in children." | 7.71 | The use of short-acting nifedipine in pediatric patients with hypertension. ( Blaszak, RT; Ellis, EN; Savage, JA, 2001) |
| "Fifteen-day-old Fischer rats were treated orally with single or combined applications of CsA, nifedipine, and/or diltiazem for 40 days; and induced gingival overgrowth, rat growth, and blood drug levels were compared among the different experimental groups." | 7.70 | Effects of combined oral treatments with cyclosporine A and nifedipine or diltiazem on drug-induced gingival overgrowth in rats. ( Amano, A; Daikoku, H; Fujimori, Y; Fukui, N; Morisaki, I; Murakami, J, 2000) |
| "We have used the model of L-2-chloropropionic acid (L-CPA)-induced selective cerebellar granule necrosis to study excitatory amino acid-induced necrotic cell death in vivo produced by the activation of N-methyl-D-aspartate (NMDA) receptors." | 7.69 | L-2-chloropropionic acid-induced cerebellar granule cell necrosis is potentiated by L-type calcium channel antagonists. ( Gyte, A; Moores, R; Pitts, M; Smith, JC; Upton, R; Widdowson, PS; Wyatt, I, 1997) |
| "Although the calcium antagonist nifedipine has been reported to suppress preterm labor, little is known of the effects of long-term nifedipine use in late pregnancy." | 7.68 | The effects of nifedipine on pregnancy outcome and morphology of the placenta, uterus, and cervix during late pregnancy in the rat. ( Richichi, J; Vasilenko, P, 1992) |
| " The pressor response to norepinephrine and angiotensin II, as well as several other blood pressure modulating factors, were studied in normal subjects (n = 9) and patients with essential hypertension (n = 10) before and after 8 weeks of treatment with the long-acting dihydropyridine amlodipine." | 7.68 | Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. ( Beretta-Piccoli, C; Bühler, FR; Donati, L; Heinen, G; Kusch, F, 1992) |
| "Weekly subcutaneous implantation of 25-mg nitrendipine pellets prevented onset of both spontaneous and deoxycorticosterone-salt hypertension in rats." | 7.67 | Control of spontaneous and deoxycorticosterone-salt hypertension and polyuria by nitrendipine pellets. ( Hall, CE; Hungerford, S, 1984) |
| "The effects of chronic dietary salt-loading and nifedipine therapy on hypertension-prone (SBH), -resistant (SBN) and parental (SB) Sabra rats were investigated." | 7.67 | Salt-induced hypertension in the 'Sabra' rat strain: influence of nifedipine treatment. ( Ben-Ishay, D; Ebsen, W; Garthoff, B; Kazda, S; Luckhaus, G, 1985) |
| "Treatment with enalapril for 48 months may have a beneficial effect on the decline of microalbumin excretion in NIDDM patients." | 6.67 | Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. ( Hara, T; Hotta, N; Kawamura, T; Matsumae, H; Matsuo, S; Nakayama, M; Sakamoto, N; Sano, T; Sasaki, H, 1994) |
| "Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure." | 6.67 | Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994) |
| "Bendroflumethiazide 5 mg was given to 17 patients with essential hypertension who had persistent mild to moderate hypertension despite treatment with nifedipine slow-release tablets 20 mg bid." | 6.66 | The effects of bendroflumethiazide added to nifedipine in patients with hypertension. ( Beevers, DG; Gill, JS; Zezulka, AV, 1987) |
| "We have assessed the efficacy and tolerance of Nifedipine twice daily and Nisoldipine once daily, both alone and in combination with a beta-blocker in 171 essential hypertensives in a randomized parallel comparison fashion." | 6.66 | The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study. ( Rosenfeld, JB; Zabludowski, J, 1989) |
| "Nifedipine-treated obese males showed a mild but significant decrease in weight gain that was due to a decrease in fat deposition in both subcutaneous and abdominal depots and systolic blood pressure was significantly reduced after one month of treatment." | 5.29 | Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. ( Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993) |
| "Nifedipine (10 mg/kg) was administered intraperitoneally every day." | 5.29 | The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats. ( Harada, Y; Inoue, M; Mori, C; Tanaka, O; Watanabe, K, 1993) |
| " The study was designed to establish a correlation between body weight and nifedipine plasma level." | 5.20 | Pharmacokinetics of nifedipine slow-release during sustained tocolysis. ( Kwee, A; Lotgering, FK; Mol, BW; Papatsonis, DN; Porath, MM; Roos, C; Spaanderman, ME; ter Laak, MA; Touw, DJ; van 't Veer, NE; van der Post, JA; van Hattum, PR; van Pampus, MG, 2015) |
| "Amiloride and chlorthalidone pretreatment induced marked volume depletion, with a 2-3% reduction in body weight, a 5-10% increase in haematocrit and a 14-23% increase in plasma colloid osmotic pressure." | 5.11 | Foot volume increase on nifedipine is not prevented by pretreatment with diuretics. ( Huysmans, FT; van der Heijden, AG; van Hamersvelt, HW, 2004) |
| " In this double-blind forced titration study design we compared the effects of mibefradil 50, 100, and 150 mg and nifedipine GITS 30, 60, and 90 mg monotherapies or combined with lisinopril 20 mg in 71 moderate to severe hypertensives (59 men and 12 women) with confirmed ambulatory hypertension." | 5.08 | The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. ( Archambault, F; Dalle Ave, S; Lacourcière, Y; Lefebvre, J; Lindberg, E; Poirier, L; Ward, C, 1997) |
| "To evaluate the metabolic effects of two anti-hypertensive agents with different actions, nifedipine 20 mg twice daily and furosemide 60 mg twice daily, 23 patients with untreated essential hypertension performed a double-blind, cross-over study in treatment periods of 5 months." | 5.08 | Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1995) |
| "Forty-nine patients, with ages ranging from eighteen to seventy years and with mild to moderate primary hypertension (sitting diastolic blood pressure of greater than or equal to 95 mmgH and less than or equal to 115 mmHg) were randomized into a twenty-one-week, double-blind, prospective study to determine the effects of monotherapy of nifedipine GITS (gastrointestinal therapeutic system) versus atenolol on serum lipids, lipid subfractions, apolipoproteins, (apo), and blood pressure (BP)." | 5.07 | Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. ( Burger, MC; Houston, MC; Olafsson, L, 1991) |
| " Ketanserin or slow-release nifedipine were added to the treatment of 24 patients with hypertension uncontrolled by a thiazide diuretic plus beta-adrenoceptor antagonist in an observer-blind, randomised parallel-group study of 6 months duration." | 5.06 | Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker. ( Ramsay, LE; Solomon, SA; Waller, PC, 1987) |
| "Nifedipine, in the gastrointestinal therapeutic system (GITS) formulation, a controlled-release formulation for once-a-day administration, was evaluated in the Modern Approach to the Treatment of Hypertension (MATH) trial." | 5.06 | Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. ( Bravo, EL; Friedman, CP; Krakoff, LR; Tuck, ML, 1990) |
| "Thirty-nine patients with mild to moderate essential hypertension participated in a parallel, single-blind study comparing 6 weeks' treatment of nicardipine hydrochloride (90 mg/day) with nifedipine (40 mg/day)." | 5.06 | Comparison of the efficacy of nicardipine, a new calcium channel blocker, with nifedipine in the treatment of mild to moderate essential hypertension. ( Armstrong, C; Blackwood, R; Garnham, J, 1987) |
| "The effects of the addition of a calcium entry antagonist, nifedipine (20-mg tablet twice a day), to an angiotensin converting enzyme inhibitor, captopril (25 mg three times a day), and the addition of captopril to nifedipine were observed in two separate studies in patients with essential hypertension." | 5.06 | Captopril and nifedipine in combination for moderate to severe essential hypertension. ( MacGregor, GA; Markandu, ND; Shore, AC; Singer, DR, 1987) |
| "Because captopril alone does not control blood pressure in all patients with essential hypertension, studies were performed to assess the effect of sodium intake and of captopril combined with hydrochlorothiazide, propranolol, and nifedipine." | 5.05 | Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. ( MacGregor, GA; Markandu, ND; Sagnella, GA; Smith, SJ, 1985) |
| "The efficacy and safety of a new slow-release formulation of nifedipine ("Adalat Retard") were assessed in a double-blind cross-over trial in 19 subjects with essential hypertension (14 male, 5 female--ages: 34-72 years), 14 of whom continued previous antihypertensive medication." | 5.05 | Slow-release nifedipine as a single or additional agent in the treatment of essential hypertension--a placebo-controlled crossover study. ( Bune, AJ; Chalmers, JP; West, MJ; Wing, LM, 1985) |
| "A controlled multicentre trial was organised to compare the effects of 20 mg Nifedipine tablets (N) and 2,5 mg Indapamide tablets (I) during a 4 months' treatment period after a placebo period, in 59 patients with moderate essential hypertension (n = 59)." | 5.05 | [Comparative effects of nifedipine and indapamide in the treatment of arterial hypertension]. ( Aubert, P; Chaignon, M; Guédon, J; Lucsko, M; Rapoud, JP, 1985) |
| "The aim of this study was to test the efficacy of a 20 mg tablet preparation of nifedipine alone in twice daily dosage, in the treatment of moderate hypertension (95 greater than or equal to DBP less than or equal to 115 mmHg)." | 5.05 | [Antihypertensive effect of a new form of nifedipine compared to a beta-blocker during chronic administration]. ( Bénichou, M; Griener, L; Kerihuel, JC; Perchicot, E; Serradimigni, A, 1985) |
| "The aim of this study was to compare the new vasodilator felodipine with nifedipine in 18 patients with poorly controlled hypertension." | 5.05 | Comparative trial of felodipine and nifedipine in refractory hypertension. ( Aberg, H; Lindsjö, M; Mörlin, B, 1985) |
| "Fifty-one patients with essential hypertension, 22 males and 29 females with a mean age of 51 (range, 28 to 65 years), were studied for more than 12 months in a controlled clinical trial with nitrendipine, a new calcium antagonist agent." | 5.05 | Clinical experience with long-term nitrendipine treatment in essential hypertension. ( Lasaridis, A; Settas, L; Tourkantonis, A, 1984) |
| "In a double-blind, cross-over study for 6 weeks that included 28 patients with essential hypertension, WHO stage I-II, the hypotensive action of verapamil (160 mg thrice daily) was compared with nifedipine (20 mg slow release twice daily)." | 5.05 | Verapamil compared with nifedipine in the treatment of essential hypertension. ( Hals, O; Midtbø, K; van der Meer, J, 1982) |
| "The effectiveness and tolerability of nitrendipine (Bay e 5009) and atenolol in the treatment of mild or moderate arterial hypertension in monotherapy and in association were evaluated in a randomized double-blind study." | 5.05 | Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension. ( de Divitiis, O; Di Somma, S; Fazio, S; Galderisi, M; Petitto, M; Santomauro, M; Villari, B, 1985) |
| "Prepubertal male mice were fed Ca²(+) channel blockers nifedipine and ethosuximide for 20 days at dosages below maximum tolerated dose (MTD) and assayed for gross morphological changes in the testis such as body weight, testis size and weight." | 3.77 | Effects of L- and T-type Ca²(+) channel blockers on spermatogenesis and steroidogenesis in the prepubertal mouse testis. ( Ahn, HJ; Gye, MC; Lee, JH; Lee, SJ; Min, CK, 2011) |
| " The present study was undertaken to examine the efficacy of nifedipine, a dihydropyridine CCB, on obesity, glucose intolerance and vascular endothelial dysfunction in db/db mice (a mouse model of obesity and type 2 diabetes)." | 3.76 | Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O, 2010) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 3.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 3.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| " Reduction of microalbuminuria at 27 weeks, compared to the vehicle group, was 37% and 52% in the enalapril- and nilvadipine-treated groups, respectively." | 3.72 | Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes. ( Imai, E; Moriyama, T; Oka, K; Ueda, H, 2004) |
| "To evaluate the use of short-acting nifedipine for treatment of severe hypertension in children." | 3.71 | The use of short-acting nifedipine in pediatric patients with hypertension. ( Blaszak, RT; Ellis, EN; Savage, JA, 2001) |
| " Enalapril and losartan reduced proteinuria but nifedipine did not." | 3.71 | Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. ( Campbell, DJ; Mackie, FE; Meyer, TW, 2002) |
| "Cyclosporine (CsA) (45 mg/kg/day for 7 days) administration in female Wistar rats induced significant decrease in creatinine clearance (Ccr) and body weight loss (BWL)." | 3.70 | Effect of nifedipine in cyclosporine-induced nephrotoxicity in rats: roles of the thromboxane and endothelin systems. ( Darlametsos, IE; Papanikolaou, EN; Varonos, DD, 2000) |
| "The effects of the Ca2+ channel blockers diltiazem, nifedipine and amlodipine were investigated on both arterial hypertension and myocardial changes induced by chronic blockade of nitric oxide synthesis." | 3.70 | Effect of Ca2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic blockade of nitric oxide in the rat. ( Antunes, E; de Luca, IM; de Nucci, G; de Oliveira, CF; Metze, K; Moreno, H; Nathan, LP; Sucupira, M; Zappellini, A; Zatz, R, 1999) |
| "Fifteen-day-old Fischer rats were treated orally with single or combined applications of CsA, nifedipine, and/or diltiazem for 40 days; and induced gingival overgrowth, rat growth, and blood drug levels were compared among the different experimental groups." | 3.70 | Effects of combined oral treatments with cyclosporine A and nifedipine or diltiazem on drug-induced gingival overgrowth in rats. ( Amano, A; Daikoku, H; Fujimori, Y; Fukui, N; Morisaki, I; Murakami, J, 2000) |
| " Accordingly, we determined the effect of Ca2+ channel blockade (nifedipine for 4 wk) on FAS and obesity in transgenic mice expressing the agouti gene in a ubiquitous manner." | 3.69 | The effects of calcium channel blockade on agouti-induced obesity. ( Kim, JH; Moore, JW; Moustaid, N; Mynatt, RL; Woychik, RP; Zemel, MB, 1996) |
| " Mibefradil treatment resulted in lower blood pressure, reduced cardiac hypertrophy, near-normal structure of conduit and small arteries and lower endothelin-1 mRNA abundance." | 3.69 | Effect of antihypertensive treatment and N omega-nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats. ( Li, JS; Schiffrin, EL; Sventek, P, 1996) |
| "We have used the model of L-2-chloropropionic acid (L-CPA)-induced selective cerebellar granule necrosis to study excitatory amino acid-induced necrotic cell death in vivo produced by the activation of N-methyl-D-aspartate (NMDA) receptors." | 3.69 | L-2-chloropropionic acid-induced cerebellar granule cell necrosis is potentiated by L-type calcium channel antagonists. ( Gyte, A; Moores, R; Pitts, M; Smith, JC; Upton, R; Widdowson, PS; Wyatt, I, 1997) |
| " The pressor response to norepinephrine and angiotensin II, as well as several other blood pressure modulating factors, were studied in normal subjects (n = 9) and patients with essential hypertension (n = 10) before and after 8 weeks of treatment with the long-acting dihydropyridine amlodipine." | 3.68 | Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. ( Beretta-Piccoli, C; Bühler, FR; Donati, L; Heinen, G; Kusch, F, 1992) |
| "Although the calcium antagonist nifedipine has been reported to suppress preterm labor, little is known of the effects of long-term nifedipine use in late pregnancy." | 3.68 | The effects of nifedipine on pregnancy outcome and morphology of the placenta, uterus, and cervix during late pregnancy in the rat. ( Richichi, J; Vasilenko, P, 1992) |
| "Eight patients with mild to moderate uncomplicated essential hypertension who had been taking nifedipine 20 mg twice daily for at least six weeks." | 3.68 | Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure. ( Buckley, MG; Cappuccio, FP; MacGregor, GA; Markandu, ND; Pevahouse, JB; Sagnella, GA, 1990) |
| "The effect of nicardipine on experimental hyperlipemia induced by a 1% cholesterol diet in spontaneously hypertensive rats (SHR) was investigated by the change of hemodynamics and the determination of lipid contents of the serum, liver, heart and aorta." | 3.67 | [Effect of nicardipine on cholesterol-fed S.H.R]. ( Kawashima, I; Nakayama, S; Ohba, T; Sakamoto, K; Tonooka, M; Yasuhara, H, 1985) |
| "Weekly subcutaneous implantation of 25-mg nitrendipine pellets prevented onset of both spontaneous and deoxycorticosterone-salt hypertension in rats." | 3.67 | Control of spontaneous and deoxycorticosterone-salt hypertension and polyuria by nitrendipine pellets. ( Hall, CE; Hungerford, S, 1984) |
| "The antihypertensive efficacy of the calcium entry blocker nitrendipine administered as monotherapy (20-80 mg; mean, 36/day) on the average for 144 days to 46 patients with essential hypertension (WHO I and II) was investigated in relation to age, pretreatment blood pressure, and plasma renin activity." | 3.67 | Antihypertensive therapy with the long-acting calcium antagonist nitrendipine. ( Block, LH; Bolli, P; Bühler, FR; Erne, P; Kiowski, W; Müller, FB, 1984) |
| "The effects of chronic dietary salt-loading and nifedipine therapy on hypertension-prone (SBH), -resistant (SBN) and parental (SB) Sabra rats were investigated." | 3.67 | Salt-induced hypertension in the 'Sabra' rat strain: influence of nifedipine treatment. ( Ben-Ishay, D; Ebsen, W; Garthoff, B; Kazda, S; Luckhaus, G, 1985) |
| "Our objective was to investigate ethnic differences in the oral pharmacokinetics of nifedipine and erythromycin, both typical cytochrome P4503A (CYP3A) substrates, in Koreans and Caucasians and to identify the nature of any correlations between the pharmacokinetic parameters of the two drugs." | 2.70 | Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. ( Bae, KS; Cho, JY; Jang, IJ; Lim, HS; Shin, SG; Shon, JH; Yi, SY; Yu, KS, 2001) |
| "Hypertension is a prevalent disease among African Americans, and successful treatment rates are low." | 2.69 | Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. ( Flack, JM; Hall, WD; Preisser, J; Reed, JW; Yunis, C, 1998) |
| "Nifedipine-treated groups also had a significant fall in blood pressure which was controlled by rehydration." | 2.67 | Enhancement of the epidural morphine-induced analgesia by systemic nifedipine. ( Dos Reis, MP; Pereira, IT; Prado, WA, 1993) |
| "Treatment with enalapril for 48 months may have a beneficial effect on the decline of microalbumin excretion in NIDDM patients." | 2.67 | Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. ( Hara, T; Hotta, N; Kawamura, T; Matsumae, H; Matsuo, S; Nakayama, M; Sakamoto, N; Sano, T; Sasaki, H, 1994) |
| "Losartan (DuP 753) is a novel orally active angiotensin II antagonist that lowers blood pressure." | 2.67 | Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. ( Carroll, J; Grossman, E; Peleg, E; Rosenthal, T; Shamiss, A, 1994) |
| "We have assessed the efficacy and tolerance of Nifedipine twice daily and Nisoldipine once daily, both alone and in combination with a beta-blocker in 171 essential hypertensives in a randomized parallel comparison fashion." | 2.66 | The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study. ( Rosenfeld, JB; Zabludowski, J, 1989) |
| "Bendroflumethiazide 5 mg was given to 17 patients with essential hypertension who had persistent mild to moderate hypertension despite treatment with nifedipine slow-release tablets 20 mg bid." | 2.66 | The effects of bendroflumethiazide added to nifedipine in patients with hypertension. ( Beevers, DG; Gill, JS; Zezulka, AV, 1987) |
| " Animals in each group daily received NIF in dimethyl sulfoxide by gastric feeding at a dosage of 0 (control), 30, or 50 mg/kg body weight for 9 weeks." | 2.40 | Nifedipine-induced gingival overgrowth in rats: brief review and experimental study. ( Fu, E; Hsiao, CT; Hsieh, YD; Nieh, S; Shen, EC; Wikesjö, UM, 1998) |
| "Nifedipine is a widely used anti-anginal and anti-hypertensive agent." | 1.40 | Nifedipine-induced histological changes in the parotid glands of hypertensive rats. ( Daskala, I; Kotsiou, A; Seferos, N; Tesseromatis, C; Tsamouri, M, 2014) |
| "The treatment with nifedipine in the CIH group attenuated blood pressure (159+/-2 mm Hg; P<0." | 1.35 | Postnatal intermittent hypoxia and developmental programming of hypertension in spontaneously hypertensive rats: the role of reactive oxygen species and L-Ca2+ channels. ( Gozal, D; Gu, Y; Nozdrachev, AD; Ortines, RV; Prabhu, SD; Soukhova-O'Hare, GK, 2008) |
| "Nifedipine was intravenously administered at a dose of 1 mg/kg." | 1.33 | Diminished responses to nifedipine imply severe end-organ damage in spontaneously hypertensive rats. ( Cai, GJ; Lu, LH; Shen, FM; Su, DF; Xie, HH, 2005) |
| "Treatment with nifedipine (30 mg/kg/day, p." | 1.31 | High salt intake impairs vascular nitric oxide/cyclic guanosine monophosphate system in spontaneously hypertensive rats. ( Kagota, S; Kunitomo, M; Nakamura, K; Tamashiro, A; Yamaguchi, Y, 2002) |
| "Enalapril was able to prevent the increase in LV and kidney weights (p=0." | 1.31 | A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin-converting enzyme inhibitor or a calcium-channel blocker. ( Jurjus, AR; Saleh, FH, 2001) |
| "Treatment with captopril (angiotensin converting enzyme inhibitor) or centhaquin (centrally acting antihypertensive agent) led to significant reduction of left ventricular hypertrophy and a marked recovery in the brain NOS activity (to 92% and 135% of the control, respectively)." | 1.30 | Attenuation in rat brain nitric oxide synthase activity in the coarctation model of hypertension. ( Dikshit, M; Hegde, LG; Shukla, R; Srimal, RC, 1997) |
| "Nifedipine was used for hypertension in 33% of SPK and was associated with better CV and amplitudes, particularly in the upper limbs, where there was less neuropathy." | 1.30 | Diabetic neuropathy after pancreas transplantation: determinants of recovery. ( Al-Harbi, IS; Allen, RD; Chapman, JR; Clouston, PD; Morris, JG; Nankivell, BJ; O'Connell, PJ, 1997) |
| " Duration of treatment, dosage of drugs per kg body weight and serum cyclosporin levels were recorded." | 1.30 | Contribution of individual drugs to gingival overgrowth in adult and juvenile renal transplant patients treated with multiple therapy. ( Ashley, FP; Koffman, CG; Morel, A; Ogg, CS; Rigden, SP; Smith, D; Wilson, RF, 1998) |
| "Nifedipine-treated obese males showed a mild but significant decrease in weight gain that was due to a decrease in fat deposition in both subcutaneous and abdominal depots and systolic blood pressure was significantly reduced after one month of treatment." | 1.29 | Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. ( Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993) |
| "Nifedipine treatment completely reversed diabetes-induced prolongation in both time-to-peak tension and time-to-90% relaxation." | 1.29 | Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium. ( Brown, RA; Lee, MM; Savage, AO; Sundareson, AM; Woodbury, DJ, 1996) |
| "Nifedipine treatment did not alter these parameters of controls, but decreased the heart weight and heart weight-to-body weight ratio of diabetic rats without affecting the body weight." | 1.29 | Impaired mechanical response to calcium of diabetic rat hearts: reversal by nifedipine treatment. ( Higa, S; Murakami, K; Nagamine, F; Shimabukuro, M; Shinzato, T; Takasu, N, 1995) |
| "Nifedipine (10 mg/kg) was administered intraperitoneally every day." | 1.29 | The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats. ( Harada, Y; Inoue, M; Mori, C; Tanaka, O; Watanabe, K, 1993) |
| "Nifedipine was administered to animals prior to treating with adriamycin." | 1.28 | Preliminary study of the protective effect of the calcium channel blocker, nifedipine, on adriamycin-induced tissue injury. ( Davis, E; Johnson, H; Parham, M; Wise, L, 1991) |
| "Hypertension was developed in 5-week-old male rats fed a low calcium diet, which evokes hypocalcemia and nutritional hyperparathyroidism, for 2 weeks." | 1.28 | Elevation of blood pressure in young rats fed a low calcium diet. Effects of nifedipine and captopril. ( Arai, M; Matsumoto, S; Nagatsu, T; Shamoto, T; Togari, A, 1989) |
| " The log dose-response relationship of S." | 1.28 | Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits. ( Emura, S; Higuchi, N; Kato, H; Ohmori, K; Ohta, Y; Oogushi, K; Sunaga, T; Takashima, T, 1990) |
| "Nifedipine was given for 20 weeks, mixed into commercial rat chow (0." | 1.27 | Improved myocardial capillarisation in spontaneously hypertensive rats treated with nifedipine. ( Hoofd, L; Kazda, S; Kubat, K; Rakusan, K; Turek, Z, 1987) |
| " A clear species difference in LD50 values was found in acute toxicity of PP-1466, and rabbits were the most sensitive between animal species used, then dogs, mice and rats in order." | 1.27 | Acute and subacute toxicity of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)-1 ,4-dihydropyridine (PP-1466). ( Aikawa, K; Fujikura, M; Gomi, T; Hirao, A; Kobayashi, M; Okumura, M; Ozeki, M; Tateishi, T; Yamamoto, H; Yumoto, S, 1985) |
| "Nifedipine was more potent in inhibiting the contraction to K+ and serotonin in WKY diabetic arteries as compared with WKY controls." | 1.27 | Effect of diabetes on vascular smooth muscle function in normotensive and spontaneously hypertensive rat mesenteric artery. ( Agrawal, DK; McNeill, JH, 1987) |
| "Nifedipine is a stronger inhibitor than verapamil as regards phagocytosis and enzyme release induced by A 23187 as well as chemotactic peptide, but with respect to fluoride-induced enzyme release verapamil was stronger inhibitor." | 1.26 | Interference of the calcium antagonists verapamil and nifedipine with lysosomal enzyme release from rabbit polymorphonuclear leukocytes. ( Elferink, JG, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (33.33) | 18.7374 |
| 1990's | 49 (42.98) | 18.2507 |
| 2000's | 20 (17.54) | 29.6817 |
| 2010's | 7 (6.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, X | 1 |
| Fu, Y | 1 |
| Liao, D | 1 |
| Chen, Y | 1 |
| Liu, J | 1 |
| Seferos, N | 1 |
| Daskala, I | 1 |
| Kotsiou, A | 1 |
| Tsamouri, M | 1 |
| Tesseromatis, C | 1 |
| ter Laak, MA | 1 |
| Roos, C | 1 |
| Touw, DJ | 1 |
| van Hattum, PR | 1 |
| Kwee, A | 1 |
| Lotgering, FK | 1 |
| Mol, BW | 1 |
| van Pampus, MG | 1 |
| Porath, MM | 1 |
| Spaanderman, ME | 1 |
| van der Post, JA | 1 |
| Papatsonis, DN | 1 |
| van 't Veer, NE | 1 |
| Lee, JH | 1 |
| Ahn, HJ | 1 |
| Lee, SJ | 1 |
| Gye, MC | 1 |
| Min, CK | 1 |
| Marçal, DM | 1 |
| Rizzi, E | 1 |
| Martins-Oliveira, A | 1 |
| Ceron, CS | 1 |
| Guimaraes, DA | 1 |
| Gerlach, RF | 1 |
| Tanus-Santos, JE | 1 |
| Yamamoto, E | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Fukuda, M | 1 |
| Nako, H | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Xu, H | 1 |
| Garver, H | 1 |
| Galligan, JJ | 1 |
| Fink, GD | 1 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Ito, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
| van der Heijden, AG | 1 |
| Huysmans, FT | 1 |
| van Hamersvelt, HW | 1 |
| Moriyama, T | 1 |
| Oka, K | 1 |
| Ueda, H | 1 |
| Imai, E | 1 |
| Okuda, N | 1 |
| Hayashi, T | 1 |
| Mori, T | 1 |
| Inamoto, S | 1 |
| Okabe, M | 2 |
| Mieno, S | 1 |
| Horimoto, H | 1 |
| Kitaura, Y | 1 |
| Lu, LH | 1 |
| Xie, HH | 1 |
| Cai, GJ | 1 |
| Shen, FM | 1 |
| Su, DF | 1 |
| Radin, MJ | 1 |
| Chu, YY | 1 |
| Hoepf, TM | 1 |
| McCune, SA | 1 |
| Francini, F | 1 |
| Gagliardino, JJ | 1 |
| Borelli, MI | 1 |
| Kametaka, S | 1 |
| Kasahara, T | 1 |
| Ueo, M | 1 |
| Takenaka, M | 1 |
| Saito, M | 1 |
| Sakamoto, K | 2 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Soukhova-O'Hare, GK | 1 |
| Ortines, RV | 1 |
| Gu, Y | 1 |
| Nozdrachev, AD | 1 |
| Prabhu, SD | 1 |
| Gozal, D | 1 |
| Müller, FB | 1 |
| Bolli, P | 1 |
| Erne, P | 1 |
| Block, LH | 1 |
| Kiowski, W | 1 |
| Bühler, FR | 2 |
| Weber, MA | 1 |
| Drayer, JI | 1 |
| Tourkantonis, A | 1 |
| Lasaridis, A | 1 |
| Settas, L | 1 |
| Fritschka, E | 1 |
| Distler, A | 1 |
| Gotzen, R | 1 |
| Thiede, HM | 1 |
| Philipp, T | 1 |
| Midtbø, K | 1 |
| Hals, O | 1 |
| van der Meer, J | 1 |
| Nickerson, PA | 1 |
| Kobrin, I | 1 |
| Sesoko, S | 1 |
| Pegram, BL | 1 |
| Frohlich, ED | 1 |
| Hall, CE | 1 |
| Hungerford, S | 1 |
| Elferink, JG | 1 |
| Luckhaus, G | 2 |
| Garthoff, B | 2 |
| Kazda, S | 3 |
| Klugmann, S | 1 |
| Bartoli Klugmann, F | 1 |
| Decorti, G | 1 |
| Gori, D | 1 |
| Silvestri, F | 1 |
| Camerini, F | 1 |
| Pijl, AJ | 1 |
| Hendriks, MG | 1 |
| Kam, KL | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| Grossman, E | 2 |
| Peleg, E | 1 |
| Carroll, J | 1 |
| Shamiss, A | 1 |
| Rosenthal, T | 2 |
| Lind, L | 1 |
| Berne, C | 1 |
| Pollare, T | 1 |
| Lithell, H | 1 |
| Petitjean, P | 1 |
| Vloemans, M | 1 |
| Barthelmebs, M | 1 |
| Stephan, D | 1 |
| Grima, M | 1 |
| Jund, A | 1 |
| Imbs, JL | 1 |
| Cappuccio, FP | 2 |
| Antonios, TF | 1 |
| Markandu, ND | 4 |
| Folkerd, EJ | 1 |
| Sagnella, GA | 3 |
| Sampson, B | 1 |
| MacGregor, GA | 4 |
| Sano, T | 1 |
| Kawamura, T | 1 |
| Matsumae, H | 1 |
| Sasaki, H | 1 |
| Nakayama, M | 1 |
| Hara, T | 1 |
| Matsuo, S | 1 |
| Hotta, N | 1 |
| Sakamoto, N | 1 |
| Porta, R | 1 |
| Conz, A | 1 |
| Conto, A | 1 |
| Pescador, R | 1 |
| Mantovani, M | 1 |
| Ferro, L | 1 |
| Kalra, A | 1 |
| Dubey, ML | 1 |
| Ganguly, NK | 1 |
| Mohan, K | 1 |
| Mahajan, RC | 1 |
| Pereira, IT | 1 |
| Prado, WA | 1 |
| Dos Reis, MP | 1 |
| Inoue, M | 1 |
| Harada, Y | 1 |
| Watanabe, K | 1 |
| Mori, C | 1 |
| Tanaka, O | 1 |
| Johnson, PL | 1 |
| Bhattacharya, SK | 1 |
| Kaymaz, AA | 1 |
| Tan, H | 1 |
| Altuğ, T | 1 |
| Büyükdevrim, AS | 1 |
| Suzuki, T | 1 |
| Mizoguchi, H | 1 |
| Motegi, H | 1 |
| Awano, H | 1 |
| Misawa, M | 1 |
| Shimabukuro, M | 1 |
| Shinzato, T | 1 |
| Higa, S | 1 |
| Nagamine, F | 1 |
| Murakami, K | 1 |
| Takasu, N | 1 |
| Brown, RA | 1 |
| Lee, MM | 1 |
| Sundareson, AM | 1 |
| Woodbury, DJ | 1 |
| Savage, AO | 1 |
| Okopién, B | 1 |
| Trzeciak, HI | 1 |
| Li, JS | 1 |
| Sventek, P | 1 |
| Schiffrin, EL | 1 |
| Kim, JH | 1 |
| Mynatt, RL | 1 |
| Moore, JW | 1 |
| Woychik, RP | 1 |
| Moustaid, N | 1 |
| Zemel, MB | 1 |
| Lacourcière, Y | 1 |
| Poirier, L | 1 |
| Lefebvre, J | 1 |
| Archambault, F | 1 |
| Dalle Ave, S | 1 |
| Ward, C | 1 |
| Lindberg, E | 1 |
| Allen, RD | 1 |
| Al-Harbi, IS | 1 |
| Morris, JG | 1 |
| Clouston, PD | 1 |
| O'Connell, PJ | 1 |
| Chapman, JR | 1 |
| Nankivell, BJ | 1 |
| Takahashi, T | 1 |
| Tanikawa, S | 1 |
| Takahashi, K | 1 |
| Hegde, LG | 1 |
| Shukla, R | 1 |
| Srimal, RC | 1 |
| Dikshit, M | 1 |
| Widdowson, PS | 1 |
| Gyte, A | 1 |
| Upton, R | 1 |
| Smith, JC | 1 |
| Pitts, M | 1 |
| Moores, R | 1 |
| Wyatt, I | 1 |
| Wilson, RF | 1 |
| Morel, A | 1 |
| Smith, D | 1 |
| Koffman, CG | 1 |
| Ogg, CS | 1 |
| Rigden, SP | 1 |
| Ashley, FP | 1 |
| Fu, E | 1 |
| Nieh, S | 1 |
| Hsiao, CT | 1 |
| Hsieh, YD | 1 |
| Wikesjö, UM | 1 |
| Shen, EC | 1 |
| Dove, LS | 1 |
| Abbott, LC | 1 |
| Griffith, WH | 1 |
| Hall, WD | 1 |
| Reed, JW | 1 |
| Flack, JM | 1 |
| Yunis, C | 1 |
| Preisser, J | 1 |
| Murphy, RJ | 1 |
| Béliveau, L | 1 |
| Gardiner, PF | 1 |
| Calderone, A | 1 |
| de Oliveira, CF | 1 |
| Nathan, LP | 1 |
| Metze, K | 1 |
| Moreno, H | 1 |
| de Luca, IM | 1 |
| Sucupira, M | 1 |
| Zatz, R | 1 |
| Zappellini, A | 1 |
| Antunes, E | 1 |
| de Nucci, G | 1 |
| Kalliovalkama, J | 1 |
| Kähönen, M | 1 |
| Tolvanen, JP | 1 |
| Wu, X | 1 |
| Voipio, J | 1 |
| Pekki, A | 1 |
| Doris, PA | 1 |
| Ylitalo, P | 1 |
| Pörsti, I | 2 |
| Morisaki, I | 1 |
| Fukui, N | 1 |
| Fujimori, Y | 1 |
| Murakami, J | 1 |
| Daikoku, H | 1 |
| Amano, A | 1 |
| Sánchez-Lozada, LG | 1 |
| Gamba, G | 1 |
| Bolio, A | 1 |
| Jiménez, F | 1 |
| Herrera-Acosta, J | 1 |
| Bobadilla, NA | 1 |
| Darlametsos, IE | 1 |
| Papanikolaou, EN | 1 |
| Varonos, DD | 1 |
| Hirata, A | 1 |
| Igarashi, M | 1 |
| Yamaguchi, H | 1 |
| Suwabe, A | 1 |
| Daimon, M | 1 |
| Kato, T | 1 |
| Tominaga, M | 1 |
| Saleh, FH | 1 |
| Jurjus, AR | 1 |
| Blaszak, RT | 1 |
| Savage, JA | 1 |
| Ellis, EN | 1 |
| Yu, KS | 1 |
| Cho, JY | 1 |
| Shon, JH | 1 |
| Bae, KS | 1 |
| Yi, SY | 1 |
| Lim, HS | 1 |
| Jang, IJ | 1 |
| Shin, SG | 1 |
| Misurski, DA | 1 |
| Hopfner, RL | 1 |
| Gopalakrishnan, V | 1 |
| Mackie, FE | 1 |
| Meyer, TW | 1 |
| Campbell, DJ | 1 |
| Kagota, S | 1 |
| Tamashiro, A | 1 |
| Yamaguchi, Y | 1 |
| Nakamura, K | 1 |
| Kunitomo, M | 1 |
| Pivac, N | 1 |
| Naranca, M | 1 |
| Vujic-Podlipec, D | 1 |
| Bagatin, J | 1 |
| Rumboldt, Z | 1 |
| Pedersen, OL | 1 |
| Mikkelsen, E | 1 |
| Makki, T | 1 |
| Lartaud, I | 1 |
| Bray-des Boscs, L | 1 |
| Capdeville-Atkinson, C | 1 |
| Chillon, JM | 1 |
| Hoffman, M | 1 |
| Nicolas, JP | 1 |
| Atkinson, J | 1 |
| Donati, L | 1 |
| Beretta-Piccoli, C | 1 |
| Kusch, F | 1 |
| Heinen, G | 1 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Nicholls, MG | 1 |
| Cheung, CK | 1 |
| Swaminathan, R | 1 |
| Richichi, J | 1 |
| Vasilenko, P | 1 |
| Nishimura, H | 1 |
| Kubota, J | 1 |
| Ueyama, M | 1 |
| Kawamura, K | 1 |
| Hunt, CM | 1 |
| Westerkam, WR | 1 |
| Stave, GM | 1 |
| Luheshi, GN | 1 |
| Zar, MA | 1 |
| Ruffolo, RR | 1 |
| Motley, ED | 1 |
| Nichols, AJ | 1 |
| Inazu, M | 1 |
| Sakai, Y | 1 |
| Homma, I | 1 |
| Kirschenbaum, MA | 1 |
| Roh, DD | 1 |
| Kamanna, VS | 1 |
| Johnson, H | 1 |
| Parham, M | 1 |
| Davis, E | 1 |
| Wise, L | 1 |
| Houston, MC | 1 |
| Olafsson, L | 1 |
| Burger, MC | 1 |
| Ohta, Y | 1 |
| Higuchi, N | 1 |
| Emura, S | 1 |
| Takashima, T | 1 |
| Oogushi, K | 1 |
| Kato, H | 1 |
| Ohmori, K | 1 |
| Sunaga, T | 1 |
| Arrigo, F | 1 |
| Consolo, F | 1 |
| Krakoff, LR | 1 |
| Bravo, EL | 1 |
| Tuck, ML | 1 |
| Friedman, CP | 1 |
| Pevahouse, JB | 1 |
| Buckley, MG | 1 |
| Rishi, M | 1 |
| Ahmad, A | 1 |
| Makheja, A | 1 |
| Karcher, D | 1 |
| Bloom, S | 1 |
| Wuorela, H | 1 |
| Arvola, P | 1 |
| Säynävälammi, P | 1 |
| Nurmi, AK | 1 |
| Huhtala, H | 1 |
| Laippala, P | 1 |
| Metsä-Ketelä, T | 1 |
| Vapaatalo, H | 1 |
| Hannedouche, T | 1 |
| Fillastre, JP | 1 |
| Mimran, A | 1 |
| de Tréglodé, D | 1 |
| Schardt, F | 1 |
| Rocco, S | 1 |
| Haebisch, EM | 1 |
| Alonso, CC | 1 |
| Luft, FC | 1 |
| Aronoff, GR | 1 |
| Fineberg, NS | 1 |
| Weinberger, MH | 1 |
| Ruilope, LM | 1 |
| Miranda, B | 1 |
| Garcia-Robles, R | 1 |
| Bigorra, J | 1 |
| Oliet, A | 1 |
| Alcazar, JM | 1 |
| Sancho Rof, J | 1 |
| Rodicio, JL | 1 |
| Yasujima, M | 1 |
| Abe, K | 1 |
| Kanazawa, M | 1 |
| Yoshida, K | 1 |
| Kohzuki, M | 1 |
| Sato, M | 1 |
| Takeuchi, K | 1 |
| Omata, K | 1 |
| Tsunoda, K | 1 |
| Kudo, K | 1 |
| Rosenfeld, JB | 1 |
| Zabludowski, J | 1 |
| Smith, SJ | 1 |
| Togari, A | 1 |
| Arai, M | 1 |
| Shamoto, T | 1 |
| Matsumoto, S | 1 |
| Nagatsu, T | 1 |
| Abelardo, NS | 1 |
| Ramos, EF | 1 |
| Mendoza, VL | 1 |
| Sulit, YQ | 1 |
| Mitchell, MJ | 1 |
| Hansson, BG | 1 |
| Lyngstam, G | 1 |
| Lyngstam, O | 1 |
| Rydén, L | 1 |
| Thilén, U | 1 |
| M'Buyamba-Kabangu, JR | 1 |
| Lepira, B | 1 |
| Fagard, R | 1 |
| Lijnen, P | 1 |
| Ditu, M | 1 |
| Tshiani, KA | 1 |
| Amery, A | 1 |
| Waller, PC | 1 |
| Solomon, SA | 1 |
| Ramsay, LE | 1 |
| de Divitiis, O | 1 |
| Petitto, M | 1 |
| Di Somma, S | 1 |
| Galderisi, M | 1 |
| Villari, B | 1 |
| Santomauro, M | 1 |
| Fazio, S | 1 |
| Singer, DR | 1 |
| Shore, AC | 1 |
| Janssens, M | 1 |
| Symoens, J | 1 |
| Zezulka, AV | 1 |
| Gill, JS | 1 |
| Beevers, DG | 1 |
| Armstrong, C | 1 |
| Garnham, J | 1 |
| Blackwood, R | 1 |
| Turek, Z | 1 |
| Kubat, K | 1 |
| Hoofd, L | 1 |
| Rakusan, K | 1 |
| Agrawal, DK | 1 |
| McNeill, JH | 1 |
| Ebsen, W | 1 |
| Ben-Ishay, D | 1 |
| Aberg, H | 1 |
| Lindsjö, M | 1 |
| Mörlin, B | 1 |
| Chaignon, M | 1 |
| Lucsko, M | 1 |
| Rapoud, JP | 1 |
| Aubert, P | 1 |
| Guédon, J | 1 |
| Serradimigni, A | 1 |
| Perchicot, E | 1 |
| Griener, L | 1 |
| Kerihuel, JC | 1 |
| Bénichou, M | 1 |
| Gomi, T | 1 |
| Yamamoto, H | 1 |
| Ozeki, M | 1 |
| Fujikura, M | 1 |
| Hirao, A | 1 |
| Kobayashi, M | 1 |
| Tateishi, T | 1 |
| Yumoto, S | 1 |
| Okumura, M | 1 |
| Aikawa, K | 1 |
| Wing, LM | 1 |
| Chalmers, JP | 1 |
| West, MJ | 1 |
| Bune, AJ | 1 |
| Ohba, T | 1 |
| Tonooka, M | 1 |
| Kawashima, I | 1 |
| Nakayama, S | 1 |
| Yasuhara, H | 1 |
1 review available for nifedipine and Body Weight
| Article | Year |
|---|---|
Nifedipine-induced gingival overgrowth in rats: brief review and experimental study.
Topics: Analysis of Variance; Animals; Body Weight; Calcium Channel Blockers; Disease Models, Animal; Dose-R | 1998 |
36 trials available for nifedipine and Body Weight
| Article | Year |
|---|---|
Pharmacokinetics of nifedipine slow-release during sustained tocolysis.
Topics: Adult; Bayes Theorem; Biological Availability; Body Weight; Chemistry, Pharmaceutical; Delayed-Actio | 2015 |
Foot volume increase on nifedipine is not prevented by pretreatment with diuretics.
Topics: Adult; Amiloride; Ankle; Body Weight; Calcium Channel Blockers; Chlorthalidone; Diuretics; Edema; Fe | 2004 |
Clinical experience with long-term nitrendipine treatment in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Blood Proteins; Body Weight; Calcium; Calcium Channel Blockers; Clinica | 1984 |
Crossover comparison of nitrendipine with propranolol in patients with essential hypertension.
Topics: Adult; Blood Pressure; Body Weight; Calcium Channel Blockers; Catecholamines; Humans; Hypertension; | 1984 |
Verapamil compared with nifedipine in the treatment of essential hypertension.
Topics: Adult; Body Weight; Calcium Channel Blockers; Creatinine; Double-Blind Method; Electrocardiography; | 1982 |
[Nilvadipin for nifedipine induced calf edema. Results of a double blind randomized comparative study].
Topics: Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Double-Blind Method; Edema; Female; Hea | 1994 |
Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Bod | 1994 |
Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study.
Topics: Aged; Analysis of Variance; Body Weight; Cross-Over Studies; Double-Blind Method; Female; Furosemide | 1995 |
Acute natriuretic effect of nifedipine on different sodium intakes in essential hypertension: evidence for distal tubular effect?
Topics: Adult; Aged; Blood Pressure; Body Weight; Cross-Over Studies; Double-Blind Method; Female; Humans; H | 1994 |
Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients.
Topics: Acetylglucosaminidase; Albuminuria; beta 2-Microglobulin; Blood Pressure; Body Weight; Cholesterol; | 1994 |
Enhancement of the epidural morphine-induced analgesia by systemic nifedipine.
Topics: Administration, Sublingual; Adult; Age Factors; Aged; Analgesia, Epidural; Blood Pressure; Body Weig | 1993 |
The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Body Weight; Calcium Channel B | 1997 |
Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Calcium | 1998 |
Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Asian People; Body Weight; Calcium Channel Blockers; | 2001 |
Prospective controlled trial of two nifedipine extended release formulations in the treatment of essential hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Weight; Calcium | 2002 |
Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis.
Topics: Albuminuria; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Enalapril; | 1992 |
Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Delayed-Action Preparations; Double-Blind Method | 1991 |
Long-term therapy with slow-release nifedipine in essential hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Delayed-Action Preparations; Dose-Response Relationship, D | 1990 |
Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension (MATH) Study Group.
Topics: Adult; Aged; Blood Pressure; Body Weight; Delayed-Action Preparations; Female; Heart Rate; Hemodynam | 1990 |
Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter study.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Flushing; Heart Rate; Humans; Hyperte | 1987 |
Facilitation of natriuresis with nifedipine in normal humans.
Topics: Adolescent; Aldosterone; Blood Pressure; Body Weight; Calcium; Creatinine; Humans; Male; Natriuresis | 1988 |
The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Double-Blind Method; Drug The | 1989 |
Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine.
Topics: Blood Pressure; Body Weight; Captopril; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hype | 1985 |
A comparison of felodipine and nifedipine as monotherapies for the treatment of mild to moderate hypertension.
Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Felodipine; Femal | 1989 |
Antihypertensive effect of felodipine combined with beta-blockade. A comparison between 2 and 3 daily dosages.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clin | 1985 |
Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients.
Topics: Acebutolol; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Black or | 1986 |
Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzothiadiazines; Blood Pressure; Body Weight; Clinical T | 1987 |
Nitrendipine and atenolol: comparison and combination in the treatment of arterial hypertension.
Topics: Adult; Atenolol; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinical Trials as Topic; Do | 1985 |
Captopril and nifedipine in combination for moderate to severe essential hypertension.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Captopril; Drug Administration Schedule; Drug | 1987 |
Ketanserin compared to nifedipine and methyldopa in patients aged above 50 years: two international multicentre studies. For the International Study Group.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate | 1986 |
The effects of bendroflumethiazide added to nifedipine in patients with hypertension.
Topics: Adult; Bendroflumethiazide; Blood Glucose; Blood Pressure; Body Weight; Clinical Trials as Topic; De | 1987 |
Comparison of the efficacy of nicardipine, a new calcium channel blocker, with nifedipine in the treatment of mild to moderate essential hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Female; Heart Rate; Humans; Hypertension; Male; Middle Age | 1987 |
Comparative trial of felodipine and nifedipine in refractory hypertension.
Topics: Aged; Ankle; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers; Clinica | 1985 |
[Comparative effects of nifedipine and indapamide in the treatment of arterial hypertension].
Topics: Adult; Blood Pressure; Body Weight; Clinical Trials as Topic; Diastole; Diuretics; Heart Rate; Human | 1985 |
[Antihypertensive effect of a new form of nifedipine compared to a beta-blocker during chronic administration].
Topics: Acebutolol; Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Heart Rate; | 1985 |
Slow-release nifedipine as a single or additional agent in the treatment of essential hypertension--a placebo-controlled crossover study.
Topics: Adult; Aged; Body Weight; Delayed-Action Preparations; Double-Blind Method; Female; Heart Rate; Huma | 1985 |
77 other studies available for nifedipine and Body Weight
| Article | Year |
|---|---|
Alterations of voltage-dependent calcium channel currents in basilar artery smooth muscle cells at early stage of subarachnoid hemorrhage in a rabbit model.
Topics: Animals; Basilar Artery; Blood Pressure; Body Weight; Brain; Calcium Channels; Calcium Channels, L-T | 2014 |
Nifedipine-induced histological changes in the parotid glands of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Body Weight; Disease Models, Animal; Hypertension; Male; Nifedipin | 2014 |
Effects of L- and T-type Ca²(+) channel blockers on spermatogenesis and steroidogenesis in the prepubertal mouse testis.
Topics: Animals; Body Weight; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, | 2011 |
Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.
Topics: Amlodipine; Animals; Antioxidants; Aorta, Thoracic; Blood Pressure; Body Weight; Calcium Channel Blo | 2011 |
Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dia | 2010 |
Large-conductance Ca2+-activated K+ channel beta1-subunit knockout mice are not hypertensive.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Heart; Hea | 2011 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent C | 2003 |
Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body | 2004 |
Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; C | 2005 |
Diminished responses to nifedipine imply severe end-organ damage in spontaneously hypertensive rats.
Topics: Animals; Aorta; Baroreflex; Blood Pressure; Body Weight; Calcium Channel Blockers; Hypertension; Kid | 2005 |
Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Composition; Body Constitution; Body Weight; | 1993 |
Decreased islet sensitivity to insulin in hamsters with dietary-induced insulin resistance.
Topics: Androstadienes; Animals; Body Water; Body Weight; Calcium Channel Blockers; Carbon Dioxide; Cricetin | 2008 |
Effect of nifedipine on severe experimental cataract in diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Calcium Channel Blockers; Cataract; Diabetes Me | 2008 |
Postnatal intermittent hypoxia and developmental programming of hypertension in spontaneously hypertensive rats: the role of reactive oxygen species and L-Ca2+ channels.
Topics: Animals; Antioxidants; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Ty | 2008 |
Antihypertensive therapy with the long-acting calcium antagonist nitrendipine.
Topics: Adult; Aged; Blood Pressure; Body Weight; Calcium Channel Blockers; Female; Heart Rate; Humans; Hype | 1984 |
The calcium channel blocker nitrendipine in single- and multiple-agent antihypertensive regimens: preliminary report of a multicenter study.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Body Weight; Calcium Channel Blockers; Drug Therapy, Combi | 1984 |
A low dose of a calcium antagonist (nitrendipine) ameliorates cardiac and renal lesions induced by DOC in the rat.
Topics: Animals; Blood Pressure; Body Weight; Calcium; Desoxycorticosterone; Drug Interactions; Female; Hear | 1984 |
Reduced cardiac mass by nitrendipine is dissociated from systemic or regional haemodynamic changes in rats.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Body Weight; Calcium Channel Blockers; Heart; Hemodyna | 1984 |
Control of spontaneous and deoxycorticosterone-salt hypertension and polyuria by nitrendipine pellets.
Topics: Animals; Antihypertensive Agents; Body Weight; Desoxycorticosterone; Female; Hypertension; Nifedipin | 1984 |
Interference of the calcium antagonists verapamil and nifedipine with lysosomal enzyme release from rabbit polymorphonuclear leukocytes.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Exocytosis; Female; In Vitro Techniq | 1982 |
Prevention of hypertensive vasculopathy by nifedipine in salt-loaded Dahl rats.
Topics: Animals; Blood Pressure; Body Weight; Female; Hematocrit; Hypertension; Nifedipine; Pyridines; Rats; | 1982 |
Adriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonistic drugs on ADM - induced cardiomyopathy.
Topics: Animals; Body Weight; Calcium Channel Blockers; Cardiomyopathies; Doxorubicin; Drug Interactions; Mi | 1981 |
Antiischemic effects of nifedipine in isolated working heart preparations of healthy, diabetic, and hypertensive rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiac Output; Coronary Circulation; Diabetes | 1994 |
Short-term effects of quinapril and nifedipine on early renal changes in streptozotocin-induced diabetes in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Body Weight; Carbon Dioxide; Diabe | 1994 |
Comparable beneficial effects of defibrotide and nifedipine in calcium induced atherosclerosis.
Topics: Animals; Arteriosclerosis; Body Weight; Calcium; Calcium Channel Blockers; Male; Nifedipine; Polydeo | 1994 |
Altered course of Plasmodium berghei infection by nifedipine treatment.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Erythrocytes; Female; Malaria; Male; Mice; M | 1993 |
The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats.
Topics: Acute Disease; Animals; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Ven | 1993 |
Regulation of membrane-mediated chronic muscle degeneration in dystrophic hamsters by calcium-channel blockers: diltiazem, nifedipine and verapamil.
Topics: Animals; Body Weight; Calcium; Calcium Channel Blockers; Cardiomegaly; Creatine Kinase; Cricetinae; | 1993 |
The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Ex | 1995 |
Effects of nifedipine on physical dependence on barbital or diazepam in rats.
Topics: Analysis of Variance; Animals; Barbital; Body Weight; Calcium Channel Blockers; Calcium Channels; Di | 1995 |
Impaired mechanical response to calcium of diabetic rat hearts: reversal by nifedipine treatment.
Topics: Analysis of Variance; Animals; Blood Glucose; Blood Pressure; Body Weight; Calcium; Diabetes Mellitu | 1995 |
Influence of calcium channel blocker treatment on the mechanical properties of diabetic rat myocardium.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Calcium Channel Blockers; Diabetes Mellit | 1996 |
Modification of adrenergic reactivity in rat tail artery by dietary lipids and calcium channel antagonists.
Topics: Animals; Arteries; Body Weight; Calcium Channel Blockers; Diet, Atherogenic; Dietary Fats; In Vitro | 1996 |
Effect of antihypertensive treatment and N omega-nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arteries; Blood Pressure | 1996 |
The effects of calcium channel blockade on agouti-induced obesity.
Topics: Adipose Tissue; Agouti Signaling Protein; Animals; Body Temperature; Body Weight; Calcium Channel Bl | 1996 |
Diabetic neuropathy after pancreas transplantation: determinants of recovery.
Topics: Adult; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dia | 1997 |
Protective effects of CD-832 on organ damage in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cerebrovascular Disorders; Diltiazem | 1997 |
Attenuation in rat brain nitric oxide synthase activity in the coarctation model of hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aortic Coarctation; Bloo | 1997 |
L-2-chloropropionic acid-induced cerebellar granule cell necrosis is potentiated by L-type calcium channel antagonists.
Topics: Animals; Aspartic Acid; Body Weight; Calcium Channel Blockers; Cerebellar Diseases; Cerebellum; Drug | 1997 |
Contribution of individual drugs to gingival overgrowth in adult and juvenile renal transplant patients treated with multiple therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Azathioprine; Body We | 1998 |
Whole-cell and single-channel analysis of P-type calcium currents in cerebellar Purkinje cells of leaner mutant mice.
Topics: Animals; Body Weight; Calcium Channel Blockers; Calcium Channels; Calcium Channels, N-Type; Electric | 1998 |
Nifedipine does not impede clenbuterol-stimulated muscle hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Body Weight; Calcium; Calcium Channels; Calcium C | 1999 |
Effect of Ca2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic blockade of nitric oxide in the rat.
Topics: Animals; Blood Pressure; Blood Pressure Determination; Body Weight; Calcium Channel Blockers; Diltia | 1999 |
Arterial responses in vitro and plasma digoxin immunoreactivity after losartan and enalapril treatments in experimental hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Effects of combined oral treatments with cyclosporine A and nifedipine or diltiazem on drug-induced gingival overgrowth in rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Body Weight; Calcium Channel Blockers; Cyclospo | 2000 |
Nifedipine prevents changes in nitric oxide synthase mRNA levels induced by cyclosporine.
Topics: Animals; Body Weight; Cyclosporine; Glomerular Filtration Rate; Glyceraldehyde-3-Phosphate Dehydroge | 2000 |
Effect of nifedipine in cyclosporine-induced nephrotoxicity in rats: roles of the thromboxane and endothelin systems.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Calcium Channel Blockers; Creatinine; Cyclospori | 2000 |
Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2.
Topics: Actins; Animals; Aorta, Thoracic; Blood Pressure; Body Weight; Calcium Channel Blockers; Carotid Art | 2000 |
A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin-converting enzyme inhibitor or a calcium-channel blocker.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Blood Pressure; Body Weight; Cal | 2001 |
The use of short-acting nifedipine in pediatric patients with hypertension.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Body Weight; Case-Control Studies; Child; Child | 2001 |
Attenuated agonist evoked vasoconstrictor responses in the perfused mesenteric vascular bed of streptozotocin diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Endo | 2001 |
Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykin | 2002 |
High salt intake impairs vascular nitric oxide/cyclic guanosine monophosphate system in spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Blood Vessels; Body Weight; Calcium Channel Blockers; Cycl | 2002 |
Acute and chronic effects of nifedipine in arterial hypertension.
Topics: Adult; Blood Pressure; Body Weight; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Pyr | 1978 |
Haemodynamic effects of a new dihydropyridine calcium entry blocker, S-12968-(-), in a rat model of cardiovascular calcium overload.
Topics: Animals; Blood Pressure; Body Weight; Calcium; Calcium Channel Blockers; Cardiac Output; Cholecalcif | 1992 |
Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II.
Topics: Adult; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Pressure; Body Weight; Dose-Respon | 1992 |
The effects of nifedipine on pregnancy outcome and morphology of the placenta, uterus, and cervix during late pregnancy in the rat.
Topics: Animals; Body Weight; Cervix Uteri; Collagen; Dose-Response Relationship, Drug; Female; Nifedipine; | 1992 |
Nifedipine in divided doses does not reverse left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Adrenergic Fibers; Animals; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Drug Administ | 1992 |
Effect of age and gender on the activity of human hepatic CYP3A.
Topics: Adult; Aged; Aged, 80 and over; Aging; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Body Weight; | 1992 |
The effect of streptozotocin-induced diabetes on cholinergic motor transmission in the rat urinary bladder.
Topics: Acetylcholine; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Electric Stimul | 1991 |
The effect of pertussis toxin on alpha 1-adrenoceptor-mediated vasoconstriction by the full agonist, cirazoline, and the partial agonist, (-)-dobutamine, in pithed rats.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Blood Vessels; Body Weight; Calcium Channels; Do | 1991 |
Contractile responses and calcium mobilization in renal arteries of diabetic rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1991 |
Effect of nifedipine on renal microvascular cholesterol accumulation and prostacyclin biosynthesis in cholesterol-fed rabbits.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Cholesterol; Cholesterol Esters; Cholesterol, Di | 1991 |
Preliminary study of the protective effect of the calcium channel blocker, nifedipine, on adriamycin-induced tissue injury.
Topics: Animals; Body Weight; Cecum; Doxorubicin; Hydroxyproline; Nifedipine; Proteins; Rats; Rats, Inbred B | 1991 |
Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol, Dietary; Dose-Response Rela | 1990 |
Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Female; Humans; Hy | 1990 |
Effects of reduced dietary magnesium on platelet production and function in hamsters.
Topics: Animals; Blood Platelets; Body Weight; Coronary Disease; Cricetinae; Diet; Magnesium Deficiency; Mal | 1990 |
Effects of calcium and deoxycorticosterone on blood pressure, plasma renin activity and vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Blood Vessels; Body Weight; Calcium; Desoxycorticosterone; Diuresis; Dose-R | 1990 |
[Effect of nifedipine on the cationic profile of myocardium and skeletal muscle of normal and hypertensive rats].
Topics: Animals; Blood Pressure; Body Weight; Cations; Hypertension; Ion Channels; Male; Muscles; Myocardium | 1987 |
Effects of nisoldipine on renal function in normal volunteers and essential hypertensive patients.
Topics: Adult; Blood Pressure; Body Weight; Diet, Sodium-Restricted; Glomerular Filtration Rate; Humans; Hyp | 1989 |
Effects of antihypertensive drugs on renal function and atrial natriuretic polypeptide in spontaneously hypertensive rats with renal ablation.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Calcium Ch | 1989 |
Elevation of blood pressure in young rats fed a low calcium diet. Effects of nifedipine and captopril.
Topics: Animals; Blood Pressure; Body Weight; Calcium; Captopril; Diet; Disease Models, Animal; Heart Rate; | 1989 |
Improved myocardial capillarisation in spontaneously hypertensive rats treated with nifedipine.
Topics: Animals; Body Weight; Capillaries; Coronary Circulation; Hypertension; Male; Microcirculation; Myoca | 1987 |
Effect of diabetes on vascular smooth muscle function in normotensive and spontaneously hypertensive rat mesenteric artery.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dose-Response Relationship, Dr | 1987 |
Salt-induced hypertension in the 'Sabra' rat strain: influence of nifedipine treatment.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Hypertension; Male; Myocardium; Nifedipine; Organ | 1985 |
Acute and subacute toxicity of 2,6-dimethyl-3,5-dimethoxycarbonyl-4-(o-difluoromethoxyphenyl)-1 ,4-dihydropyridine (PP-1466).
Topics: Administration, Oral; Animals; Blood Chemical Analysis; Body Weight; Calcium Channel Blockers; Dogs; | 1985 |
[Effect of nicardipine on cholesterol-fed S.H.R].
Topics: Animals; Aorta; Arteriosclerosis; Body Weight; Heart Rate; Hyperlipidemias; Hypertension; Lipids; Li | 1985 |